ASFA
JAZZ icon

All Season Financial Advisors’s Jazz Pharmaceuticals JAZZ Stock Holding History

All Season Financial Advisors’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-1,424
Closed -$222K – 149
2022
Q1 		$222K Buy
+1,424
New +$207K 0.16% 130

Other funds holding JAZZ

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PCM
Polaris Capital Management Boston, Massachusetts $1.06B AUM 40.82% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return

All Season Financial Advisors's JAZZ Position: Q2 2022 in Review

All Season Financial Advisors sold out of Jazz Pharmaceuticals (JAZZ) in Q2 2022, closing a stake of 1,424 shares — an estimated $222K sold.

All Season Financial Advisors first reported a position in JAZZ in Q1 2022 and held it in 1 quarter. The position peaked at $222K in Q1 2022. 468 funds tracked by Wall St. Rank hold JAZZ as of Q2 2022.

  • All Season Financial Advisors reported no remaining Jazz Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • All Season Financial Advisors sold 1,424 Jazz Pharmaceuticals shares in Q2 2022, an estimated $222K.
  • All Season Financial Advisors first reported a position in Jazz Pharmaceuticals in Q1 2022 and held it in 1 quarter.
  • All Season Financial Advisors's Jazz Pharmaceuticals position peaked at $222K in Q1 2022.
  • 468 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2022.

Based on All Season Financial Advisors's 13F filing for Q2 2022, filed 18 Jul 2022.